23/05/2025 – AB Science today announces the settlement and delivery of its capital increase announced on May 20, 2025 for an amount of €1.8 million, subscribed by a limited number of investors Download PDF Post navigationPreviousPrevious post:AB Science announces the successful completion of a EUR 1.8 million private placementNextNext post:AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsRelated PostsAB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025AB Science announces EMA approval of Masivet shelf-life extension to 4 yearsJune 9, 2025AB Science announces the successful completion of a EUR 1.8 million private placementMay 20, 2025AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025AB Science reports a new publication in the scientific journal PLOS OneMay 15, 2025CNews – Interview of Alain MoussyMay 12, 2025
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036June 12, 2025
AB Science receives Chinese patent protecting masitinib in the treatment of Covid-19 until 2041May 19, 2025
